Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding

International Journal of Angiology

Volumn 23, Issue 4, 2014, Pages 227-232

  Feldman, Alexander ^a   Suleiman, Khalid ^a   Bushari, Limor ^a   Yahalom, Malka ^a   Rozner, Ehud ^a   Freedberg, Nahum Adam ^a   Turgeman, Yoav ^a  

^a HAEMEK MEDICAL CENTER   (Israel)

Author keywords

bivalirudin; bleeding; high risk patient; PCI; unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOGENIC SHOCK; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FALSE ANEURYSM; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HEART INFARCTION; HEMATOMA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

EID: 84912031816     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0034-1372244     Document Type: Article

References (17)

1. Nasser T. K., Mohler E. R. III, Wilensky R. L., Hathaway D. R. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol: 1995; 18 11 609 614
2. Ellis S. G. Elective coronary angioplasty: technique and complications. In: Topol E. J. ed. Textbook of Interventional Cardiology, 2nd edition. Philadelphia, PA W.B. Saunders: 1993; 186 207
3. Bredlau C. E., Roubin G. S., Leimgruber P. P., Douglas J. S. Jr, King S. B. III, Gruentzig A. R. In-hospital morbidity and mortality in patients undergoing elective coronary angioplasty. Circulation: 1985; 72 5 1044 1052
4. Green G. S., McKinnon C. M., Rösch J., Judkins M. P. Complications of selective percutaneous transfemoral coronary arteriography and their prevention. A review of 445 consecutive examinations. Circulation: 1972; 45 3 552 557
5. Kelsey S. F., Mullin S. M., Detre K. M., et al. Effect of investigator experience on percutaneous transluminal coronary angioplasty. Am J Cardiol: 1984; 53 12 56C 64C
6. Topol E. J., Califf R. M., Weisman H. F., et al. The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet: 1994; 343 8902 881 886
7. Lincoff A. M., Tcheng J. E., Califf R. M., et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation: 1999; 99 15 1951 1958
8. Kastrati A., Mehilli J., Schühlen H., et al. Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med: 2004; 350 3 232 238
9. Lincoff A. M., Bittl J. A., Harrington R. A., et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA: 2003; 289 7 853 863
10. Stone G. W., McLaurin B. T., Cox D. A., et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med: 2006; 355 21 2203 2216
11. Kastrati A., Neumann F. J., Mehilli J., et al. ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med: 2008; 359 7 688 696
12. Kastrati A., Neumann F. J., Schulz S., et al. ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med: 2011; 365 21 1980 1989
13. Vidi V. D., Matheny M. E., Agarwal V., et al. Validation of long-term benefits of bivalirudin versus unfractionated heparin in routine clinical practice after percutaneous coronary intervention. Am J Cardiol: 2010; 106 9 1234 1240
14. Verheugt F. W., Steinhubl S. R., Hamon M., et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv: 2011; 4 2 191 197
15. Hanna E. B., Chen A. Y., Roe M. T., Wiviott S. D., Fox C. S., Saucedo J. F. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv: 2011; 4 9 1002 1008
16. Chew D. P., Lincoff A. M., Gurm H., et al. REPLACE-2 Investigators. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol: 2005; 95 5 581 585
17. Saltzman A. J., Stone G. W., Claessen B. E., et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv: 2011; 4 9 1011 1019